|1.||Baker, Sharyn D: 2 articles (09/2003 - 01/2003)|
|2.||Donehower, Ross C: 2 articles (09/2003 - 01/2003)|
|3.||Wolff, Antonio C: 2 articles (09/2003 - 01/2003)|
|4.||Zabelina, Yelena: 2 articles (09/2003 - 01/2003)|
|5.||Swindell, Charles S: 2 articles (09/2003 - 01/2003)|
|6.||Baker, S D: 2 articles (10/2001 - 07/2001)|
|7.||Webb, N L: 2 articles (10/2001 - 07/2001)|
|8.||Witman, P A: 2 articles (10/2001 - 07/2001)|
|9.||Anthony, F H: 2 articles (10/2001 - 07/2001)|
|10.||Devanesan, P: 2 articles (10/2001 - 07/2001)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/01/2006 - "As a single-agent, docosahexaenoic acid-paclitaxel has little activity in patients with advanced non-small cell lung cancer, with 18 patients (40.1%) achieving either stable disease or a partial response after treatment. "
11/01/2006 - "This prospective, open-label, non-randomized, multi-institutional phase II study was undertaken to assess the antitumor activity and safety of docosahexaenoic acid-paclitaxel (Taxoprexin) as first-line treatment of patients with advanced non-small cell lung cancer. "
11/01/2006 - "DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial."
|2.||Peripheral Nervous System Diseases (PNS Diseases)
07/06/2001 - "A phase I clinical study has been completed at The Johns Hopkins Hospital to evaluate the safety of DHA-paclitaxel in patients with a variety of solid tumors. "
09/01/2003 - "Patients with advanced refractory solid tumors received a 2-h i.v. infusion of DHA-paclitaxel every 3 weeks. "
01/01/2003 - "The blood distribution of DHA-paclitaxel was studied in vitro using equilibrium dialysis and in 23 cancer patients receiving the drug as a 2-h i.v. infusion (dose, 200-1100 mg/m(2)). "
10/01/2001 - "lung tumor model, whereas DHA-paclitaxel caused complete regressions that were sustained for 60 days in 4 of 10 mice at 60 mg/kg, 9 of 10 mice at 90 mg/kg, and 10 of 10 mice at the optimum dose of 120 mg/kg. The drug seems to be inactive as a cytotoxic agent until metabolized by cells to an active form. "
07/06/2001 - "Thus, DHA-paclitaxel is well tolerated in patients and cures tumors in mice by targeting drug to tumors."
|5.||Melanoma (Melanoma, Malignant)
08/01/2009 - "Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients."
08/01/2009 - "As a single-agent therapy, DHA-paclitaxel was well tolerated in metastatic melanoma patients. "
08/01/2009 - "We investigated the response rate and safety of weekly DHA-paclitaxel in metastatic melanoma patients. "
04/01/2011 - "Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma."
08/01/2009 - "Docosahexaenoic acid (DHA)-paclitaxel has a unique pharmacokinetic profile that allows high concentrations of paclitaxel to be delivered to melanoma cells for prolonged periods compared with paclitaxel. "